(Reuters) -Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other oral medicines.

The Indianapolis-based drugmaker has shelled out billions of dollars in recent months to boost production of orforglipron, as it proceeds with global regulatory submissions for the pill by the end of the year.

Lilly had said last week orforglipron met most criteria for the U.S. Food and Drug Administration’s new national priority voucher, which could shorten drug reviews to one to two months from about 10 to 12 months.

The new European facility would be also used to make oral medicines for diseases related to cardiometabolism, neurology, oncology and immunology, Lil

See Full Page